Straits Times Index
3,344.56 +13.75 (+0.41%) Nikkei
38,667.08 -36.43 (-0.09%) Hang Seng
18,397.20 -79.60 (-0.43%) FTSE 100
8,285.34 +38.39 (+0.47%) Bitcoin USD
71,140.06 +136.26 (+0.19%) CMC Crypto 200
1,479.08 -45.72 (-3.00%)
APLS Jan 2025 60.000 call
| Previous close | 3.2000 |
| Open | 3.2100 |
| Bid | 2.9500 |
| Ask | 3.3000 |
| Strike | 60.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.2100 - 3.2100 |
| Contract range | N/A |
| Volume | |
| Open interest | 3.61k |
ZacksWhy Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswireApellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 4:00 p.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. Abou
ZacksApellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
